Log in to search using one of your social media accounts:

 

How to manage family life when your child has cancer
Valerie, with husband Doron, son Evan and daughter Ruby When our daughter, Ruby, was diagnosed with acute lymphoblastic leukemia (ALL) at one and a half years old, my husband and I were immediately transformed from working parents with two young children, to parental caregivers for a child with cancer. Between hospital stays, medications and appointments, there was so much to keep track of. It can be overwhelming at times, but there are ways to manage life after your child is diagnosed with cancer. Settle into to this new normal. It can be easy to stay in crisis mode when something like a cancer diagnosis interrupts y...
Source: Thrive, Children's Hospital Boston - September 20, 2017 Category: Pediatrics Authors: Valerie Graf Tags: Diseases & Conditions Parenting Cancer Dana-Farber/Boston Children's Cancer and Blood Disorders Center Source Type: news

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukaemia
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukaemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukaemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL
US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 19, 2017 Category: Pharmaceuticals Source Type: news

Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - September 14, 2017 Category: American Health Source Type: news

Adult Acute Lymphoblastic Leukemia (ALL)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 14, 2017 Category: General Medicine Source Type: news

Pascal Biosciences acquires STC technology for B-cell precursor ALL treatment
Canadian drug discovery and development company Pascal Biosciences has executed an exclusive, worldwide licence option agreement with STC.UNM (STC) to purchase a therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukaemia (BCP- … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia
Kymriah (tisagenlecleucel) is the first chimeric antigen receptor T cell (CAR-T) therapy approved in the US for the treatment of paediatric and young adult patients with B-cell precursor acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

A parent ’s guide to clinical trials
Children with life-threatening conditions, such as cancer, are often candidates for clinical trials. What are they? Which factors should parents weigh in determining whether enrolling in one is a good option for their child? Dr. Steven DuBois, director of the Advancing Childhood Cancer Therapies Clinic at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, answers questions about clinical trials. What are clinical trials? Why are they important? Clinical trials are systematic, scientific investigations of new drugs or therapies for a specific disease. Through clinical trials, we have taken many fatal ped...
Source: Thrive, Children's Hospital Boston - September 1, 2017 Category: Pediatrics Authors: Irene Sege Tags: Ask the Expert Research and Innovation clinical trial Dana-Farber/Boston Children's Cancer and Blood Disorders Center Dr. Steven DuBois Source Type: news

Novartis ’ Kymriah receives FDA approval for B-cell precursor ALL treatment
The US Food and Drug Administration (FDA) has approved Novartis ’ Kymriah (tisagenlecleucel) suspension for intravenous infusion to treat patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL) that is refractory or in… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 31, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Therapy Using Patient ’ s Own Cells To Fight Cancer Cells
BOSTON (CBS) — The Dana Farber Cancer Institute and Boston Children’s Hospital will work to fight cancer in a new way thanks to a new treatment approved by the FDA. CAR-T therapy is for kids and young adults with relapsed and refractory acute lymphoblastic leukemia (ALL). “It’s really an entirely new type of therapy, an entirely new way to fight cancer,” said Dr. Lewis Silverman, the Clinical Director of the Pediatric Hematologic Malignancies Center. Chemotherapy drugs attack dividing cells but are not specific to cancer cells, unlike this new treatment, according to Silverman. “It&...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 31, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Seen On WBZ-TV Syndicated Local Boston Children's Hospital Dana Farber Cancer Institute Juli McDonald Leukemia Source Type: news

First Gene Therapy Approved in U.S. (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM The FDA on Wednesday approved tisagenlecleucel (Kymriah) for patients up to age 25 years with B cell precursor acute lymphoblastic leukemia that has relapsed or not responded … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 30, 2017 Category: Primary Care Source Type: news

HealthWatch: A New Gene Therapy For Leukemia; A Study On Carbohydrates
This study does not mean you can now eat a ton of butter and steak without worry, but you probably don’t need to feel guilty about eating some fat. In terms of carbohydrates, the study did not distinguish between refined carbs and complex carbs, so further study is needed. (Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire)
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 30, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Healthwatch Local News Seen On WBZ-TV Syndicated Local Cancer Research Dr. Mallika Marshall Leukemia Source Type: news

FDA Approves Kymriah (tisagenlecleucel) CAR-T Gene Therapy for Acute Lymphoblastic Leukemia
August 30, 2017 -- The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 30, 2017 Category: Drugs & Pharmacology Source Type: news

FDA OKs first-of-its-kind T-cell cancer therapy developed by Penn & CHOP
The Food and Drug Administration approved a personalized cellular therapy treatment for leukemia developed by researchers at the University of Pennsylvania and Children ’s Hospital of Philadelphia. The T-Cell therapy, which will be marketed by Novartis as Kymriah, was OK'd as treatment for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory, or in second or later relapse. In 2012, Penn and Novartis — a Swiss dr ug company that has its U.S headquarters… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 30, 2017 Category: American Health Authors: John George Source Type: news

First gene therapy coming to U.S. after FDA approval
The U.S. Food and Drug Administration announced today it is making the first gene therapy available in the United States to treat acute lymphoblastic leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 30, 2017 Category: Consumer Health News Source Type: news

FDA approval brings first gene therapy to the United States
The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). (Source: World Pharma News)
Source: World Pharma News - August 30, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

UChicago Medicine working to offer breakthrough CAR T-cell gene therapy approved by FDA
(University of Chicago Medical Center) The University of Chicago Medicine is one of a limited number of US sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the US Food and Drug Administration. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 30, 2017 Category: Cancer & Oncology Source Type: news

FDA approves personalized cellular therapy for advanced leukemia developed by University of Pennsylvania and Children's Hospital of Philadelphia
(University of Pennsylvania School of Medicine) In a landmark decision for the field of cancer immunotherapy, the US Food and Drug Administration today approved a personalized cellular therapy developed by the University of Pennsylvania and Children's Hospital of Philadelphia for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 30, 2017 Category: Cancer & Oncology Source Type: news

BESPONSA (inotuzumab ozogamicin) Approved for Treatment of Adult Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia, available for order at Biologics, Inc.
CARY, N.C. (August 22, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Pfizer, Inc. to be a specialty pharmacy provider for BESPONSA® (inotuzumab ozogamicin), a promising new IV therapy for adult patients with relapsed o... (Source: McKesson News)
Source: McKesson News - August 22, 2017 Category: Information Technology Source Type: news

Pfizer ’s Besponsa gets FDA approval for treatment of B-cell precursor ALL
The US Food and Drug Administration has given approval for Pfizer ’s Besponsa (inotuzumab ozogamicin) to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 20, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves New Acute Lymphoblastic Leukemia Treatment
The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - August 18, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

New treatment approved for deadly blood cancer
The FDA approved the anti-cancer drug Besponsa, or inotuzumab ozogamicin, to treat B-cell acute lymphoblastic leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 18, 2017 Category: Consumer Health News Source Type: news

FDA Approves New Treatment for Acute Lymphoblastic Leukemia
For patients with relapsed or refractory B - cell ALL who have received one or two prior treatments (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 18, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

FDA Approves Inotuzumab Ozogamicin (Besponsa) for ALL FDA Approves Inotuzumab Ozogamicin (Besponsa) for ALL
The new drug is for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). These patients have a very poor prognosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia
August 17, 2017 -- The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). “For adult patients with B-cell... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 17, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. (Source: World Pharma News)
Source: World Pharma News - August 17, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

New Treatment Approved for Deadly Blood Cancer
Acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 17, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

New Treatment Approved for Deadly Blood Cancer
Acute lymphoblastic leukemia Source: HealthDay Related MedlinePlus Pages: Acute Lymphocytic Leukemia, Cancer Immunotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 17, 2017 Category: Consumer Health News Source Type: news

FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 17, 2017 Category: American Health Source Type: news

Besponsa (Inotuzumab Ozogamicin) Approved for Deadly Blood Cancer
THURSDAY, Aug. 17, 2017 -- The U.S. Food and Drug Adminstration on Thursday approved the anti-cancer drug Besponsa (inotuzumab ozogamicin) to treat B-cell acute lymphoblastic leukemia (ALL). B-cell ALL is a rapidly growing cancer that occurs when... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 17, 2017 Category: General Medicine Source Type: news

Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults
(Seattle Children's) After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent. Researchers have opened a phase 1 trial, PLAT-04, for children and young adults with relapsed or refractory CD22-positive ALL. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 27, 2017 Category: Biology Source Type: news

Drug for Relapsed, Refractory ALL Increased Hepatotoxicity
Treatment of adult relapsed or refractory acute lymphoblastic leukemia with inotuzumab ozogamicin was associated with increased hepatotoxicity, especially after follow-up hematopoietic stem cell transplantation. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Blinatumomab Gets Full FDA Approval for B-Cell Precursor ALL
The FDA has expanded the approval of blinatumomab (Blincyto) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. (Source: CancerNetwork)
Source: CancerNetwork - July 14, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Hematologic Malignancies Leukemia & Lymphoma News Pediatric Cancers Source Type: news

FDA recommends approval for Novartis ’ CTL019 to treat r/r B-cell ALL
The US Food and Drug Administration ’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended approval of Novartis’ CTL019 (tisagenlecleucel) for the treatment of relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news

FDA panel recommends approval for experimental leukemia treatment
The first treatment to genetically alter a patient's own cells, to fight relapsed B-cell acute lymphoblastic leukemia, is one step closer to FDA approval. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 13, 2017 Category: Consumer Health News Source Type: news

FDA panel recommends approval for gene-altering cancer treatment
An FDA advisory panel yesterday recommended approval for Novartis‘ (NYSE:NVS) CAR-T gene therapy. If approved, it would be the first ever treatment of its kind on the market. The panel voted unanimously, 10-0, to recommend that the FDA give its official nod. The company’s therapy genetically alters a patient’s own cells to fight acute lymphoblastic leukemia. Get the full story at our sister site, Drug Delivery Business News. The post FDA panel recommends approval for gene-altering cancer treatment appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Oncology Regulatory/Compliance Wall Street Beat Novartis Source Type: news

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL). (Source: World Pharma News)
Source: World Pharma News - July 12, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

FDA Grants Full Approval for BLINCYTO ® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children
BLINCYTO is the First-and-Only Bispecific T Cell Engager (BiTE®) Immunotherapy to Demonstrate Superior Overall Survival Versus Standard of Care Chemotherapy Data From the Phase 3 TOWER Study Support Conversion From Accelerated to Full Approval Indication Expansion Underscores Need for Effective Treatment Options THOUSAND OAKS, Calif., July 11, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include overall survival (OS) data from the Phase 3 ...
Source: Amgen News Release - July 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novartis readies for FDA review of $1 billion CAR-T child cancer hope
ZURICH (Reuters) - Two decades ago in a Memphis, Tenn., hospital lab, cancer scientist Dario Campana and his team were hunting for a new way to fight deadly acute lymphoblastic leukemia (ALL). (Source: Reuters: Health)
Source: Reuters: Health - July 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children
THOUSAND OAKS, Calif., July 11, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 11, 2017 Category: Drugs & Pharmacology Source Type: news

BESPONSA ® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Pfizer Inc. (NYSE:PFE) announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). This indication includes treatment of adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell precursor ALL. (Source: World Pharma News)
Source: World Pharma News - July 7, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

EC approves Pfizer ’s acute lymphoblastic leukemia treatment Besponsa
The European Commission (EC) has approved Pfizer ’s Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in the European Union (EU). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 3, 2017 Category: Pharmaceuticals Source Type: news

First large-scale genomic analysis of key acute leukemia will likely yield new therapies
(St. Jude Children's Research Hospital) Charting the genomic landscape of T-lineage acute lymphoblastic leukemia patients revealed insights that will guide research and help to lay the foundation for more targeted therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 3, 2017 Category: International Medicine & Public Health Source Type: news

Adult ALL Patients Benefited From Pediatric Regimen Treatment Intensification
Adult patients with early thymic precursor (ETP) acute lymphoblastic leukemia (ALL), a subgroup of T-cell ALL, could benefit from the use of response-based risk stratification and therapy intensification similar to that used in pediatric patients with ETP-ALL. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Amgen To Present New Data At 22nd Congress of the European Hematology Association
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma New Subset Analysis Demonstrates BLINCYTO® (Blinatumomab) More Than Doubled Median Overall Survival Versus Standard of Care Chemotherapy in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage Oral Presentation of New Data From Head-to-Head Phase 3 Study of XGEVA® (Denosumab) Versus Zoledronic Acid in Time to First On-Study Skeletal...
Source: Amgen News Release - June 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New cancer drug tested in mice may benefit certain leukemia patients
(University of Utah Health) Scientists have found up to 30 percent of adult acute lymphoblastic leukemia or ALL patients have Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. Adult ALL patients often see high relapse rates, and treatment-related deaths remain high. Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have discovered new science, published this week in the journal Leukemia, that could provide better therapeutic options for patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2017 Category: Cancer & Oncology Source Type: news

MRD Status Indicated Therapeutic Benefit in Pediatric, Adult ALL
There is considerable value in having achieved a minimal residual disease negativity for pediatric and adult patients with acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 14, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Trial aims to extend remission for children treated with T-cell immunotherapy for leukemia
(Seattle Children's) After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 9, 2017 Category: Biology Source Type: news

Inflammation Linked to Cognitive Difficulties in Childhood ALL Survivors
Female survivors of childhood acute lymphoblastic leukemia were at risk for neurocognitive impairment and were more susceptible to the effects of sleep disturbance and fatigue compared with their male counterparts. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Pediatric Cancers Survivorship Source Type: news

Genome-wide identification and characterization of Notch transcription complex-binding sequence-paired sites in leukemia cells
Notch transcription complexes (NTCs) drive target gene expression by binding to two distinct types of genomic response elements, NTC monomer–binding sites and sequence-paired sites (SPSs) that bind NTC dimers. SPSs are conserved and have been linked to the Notch responsiveness of a few genes. To assess the overall contribution of SPSs to Notch-dependent gene regulation, we determined the DNA sequence requirements for NTC dimerization using a fluorescence resonance energy transfer (FRET) assay and applied insights from these in vitro studies to Notch-"addicted" T cell acute lymphoblastic leukemia (T-ALL) cel...
Source: Signal Transduction Knowledge Environment - May 2, 2017 Category: Science Authors: Severson, E., Arnett, K. L., Wang, H., Zang, C., Taing, L., Liu, H., Pear, W. S., Shirley Liu, X., Blacklow, S. C., Aster, J. C. Tags: STKE Research Articles Source Type: news